PharmaCyte Biotech, Inc.PMCBNASDAQ
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank44
Year-over-Year Change
Year-over-year earnings per share growth rate
Percentile
P44
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | -0.81% |
| Q3 2025 | -176.88% |
| Q2 2025 | 463.64% |
| Q1 2025 | -12.82% |
| Q4 2024 | -120.53% |
| Q3 2024 | 693.75% |
| Q2 2024 | 50.77% |
| Q1 2024 | -150.00% |
| Q4 2023 | 51.85% |
| Q3 2023 | -7100.00% |
| Q2 2023 | -676.92% |
| Q1 2023 | 101.44% |
| Q4 2022 | -21.29% |
| Q3 2022 | 7.94% |
| Q2 2022 | -127.68% |
| Q1 2022 | 37.23% |
| Q4 2021 | 91.19% |
| Q3 2021 | -3.23% |
| Q2 2021 | -26.53% |
| Q1 2021 | 20.97% |
| Q4 2020 | 21.52% |
| Q3 2020 | -17.91% |
| Q2 2020 | 29.47% |
| Q1 2020 | 21.49% |
| Q4 2019 | 13.57% |
| Q3 2019 | 0.71% |
| Q2 2019 | -56.67% |
| Q1 2019 | 37.50% |
| Q4 2018 | 17.24% |
| Q3 2018 | 10.31% |
| Q2 2018 | 37.82% |
| Q1 2018 | -11.43% |
| Q4 2017 | -2.56% |
| Q3 2017 | -39.29% |
| Q2 2017 | 12.50% |
| Q1 2017 | -30.23% |
| Q4 2016 | 12.24% |
| Q3 2016 | 10.50% |
| Q2 2016 | 38.31% |
| Q1 2016 | -7.90% |